04/12/21 1:41 AMOTC : BOVNFBioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancerBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) at the annualRHEA-AIneutral
04/08/21 2:50 AMOTC : BOVNFBioInvent International's Annual Report 2020 publishedBioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the Annual Report for 2020 is published and available at the company's website,RHEA-AIneutral
03/31/21 2:48 AMOTC : BOVNFChange in the number of shares and votes in BioInvent International ABBioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company's total number of shares as per March 31, 2021 amounts to 58,471,096 shares, corresponding to an equal number of votes. The increase in the number of shares andRHEA-AIneutral
03/11/21 3:06 AMOTC : BOVNFBioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), today announces the publication of proof-of-concept data on a novel, fully human Fc?RIIB-blocking antibody, BI-1607, at the American Association for Cancer Research (AACR) Annual MeetingRHEA-AIpositive
03/01/21 1:52 AMOTC : BOVNFBioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumorsBioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (EuronextRHEA-AIvery positive
02/23/21 3:21 AMOTC : BOVNFBioInvent International Financial Statement January 1 - December 31, 2020"BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expandingRHEA-AIpositive
08/21/20 7:04 AMOTC : BOVNFInvitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m. CEST, hosted by Martin Welschof, CEO and members of theRHEA-AIneutral
